Central to this advancement is the reconsideration of the radiolabeling process, traditionally a painstaking and labor-intensive procedure that requires several hours of meticulous manual action to attach the radioactive lutetium-177 to a carrier molecule, known as a DOTA chelator, before combining it with the delicate targeting molecule. This conventional multi-step approach, involving elevated temperatures and cooling phases, often compromises the sensitive molecular architecture of the targeting agent due to its vulnerability to heat and acid conditions, presenting significant technical hurdles.

The research, spearheaded by Meltem Ocak and Carolyn Anderson at the University of Missouri’s Molecular Imaging and Theranostics Center, alongside CTT’s Bea Langton-Webster and ITG’s Jim Simón, introduces an ingenious single-step synthesis technique that simplifies and expedites this process. By chemically pre-linking the targeting molecule to the DOTA chelator, the team was able to radiolabel the compound by gently heating it to 60 degrees Celsius, an optimum temperature that preserves the structural integrity of the targeting moiety while allowing efficient chelation of lutetium-177.

This temperature-controlled reaction is seamlessly integrated into a commercially available automated synthesis unit housed at the University of Missouri Research Reactor (MURR), a facility renowned for its production of life-saving isotopes. The process thus reduces synthesis time from approximately six hours to a mere 38 minutes, dramatically enhancing production throughput and reproducibility. The automation not only curtails human exposure to radioactive materials, significantly improving operator safety, but also aligns with industry demands for scalable, standardized production methods requisite for extensive clinical trials.

Preclinical evaluations validated that this accelerated and automated radiolabeling method produces a radiopharmaceutical with efficacy comparable to that generated through traditional laborious techniques. This equivalency in therapeutic performance underscores the viability of the novel approach for ongoing and future clinical applications aimed at combatting advanced prostate cancer. The breakthrough presents a pivotal step toward realizing broader accessibility to targeted radiotherapies, which have been hitherto limited by complex manufacturing constraints.

Beyond the immediate application to CTT1403, this pioneering work sets a compelling precedent for the radiochemical synthesis of other targeted cancer therapeutics. The concept of developing pre-assembled chelator-targeting molecule conjugates amenable to lower-temperature and automated radiolabeling could be extrapolated to a spectrum of radiotherapeutics, expediting their bench-to-bedside translation.

Moreover, the portability of the synthesis apparatus heralds a vision where such systems could be deployed within clinical environments, such as hospitals and radiopharmacies, potentially enabling onsite production of personalized cancer treatments. This advancement promises to diminish logistical barriers and latency in drug delivery, ultimately enhancing patient access to innovative therapies in real time.

The University of Missouri’s confluence of expertise in isotopic production at MURR and radiopharmaceutical chemistry uniquely positions it as a fertile nexus for continued innovation in this domain. Carolyn Anderson, a distinguished professor and associate director at the Ellis Fischel Cancer Center, underscores the transformative impact of this work, highlighting the potential to replicate or adapt this radiolabeling protocol for diverse diagnostic and therapeutic agents using lutetium-177.

Recognition of this research includes accolades such as the Drs. Jane & Abass Alavi Mars Shot Research Award granted to Anderson, evidencing the scientific community’s appreciation for advancements in nuclear medicine and molecular imaging. The study appears in the prestigious journal Nuclear Medicine and Biology, providing a detailed blueprint of the automated one-step radiolabeling methodology, supported by funding from the National Cancer Institute.

As the oncology field increasingly gravitates toward precision medicine, methodologies that facilitate rapid, reliable, and safe synthesis of targeted radiotherapeutics will be indispensable. This research not only exemplifies such innovation but also accelerates the journey toward scalable clinical deployment of next-generation cancer treatments with enhanced efficacy and patient tolerability.

Subject of Research: People

Article Title: Development of an automated one-step radiolabeling procedure for a PSMA-targeted radiotherapeutic for prostate cancer

News Publication Date: 29-Jan-2026

Web References:
http://dx.doi.org/10.1016/j.nucmedbio.2026.109607

References:
National Cancer Institute (funder)

Image Credits:
University of Missouri

Keywords:
Biomedical engineering, Clinical medicine, Diseases and disorders, Health care, Human health, Medical specialties, Pharmaceuticals, Pharmacology, Health and medicine

Intrinsically disordered proteins defy classical paradigms, lacking a stable three-dimensional structure and instead existing as dynamic, fluctuating regions within cells. Their shapeshifting nature has made them elusive to traditional small-molecule drugs, which typically latch onto well-defined, stable binding sites. These proteins play pivotal roles in a broad spectrum of pathologies, including various cancers, neurodegenerative disorders, cardiovascular ailments, and autoimmune diseases, yet pharmaceutical interventions targeting them have remained limited and largely ineffective.

The new study, recently published in the journal Signal Transduction and Targeted Therapy, presents a pioneering approach that contravenes the lock-and-key model of drug design. By designing compounds capable of binding with extraordinary affinity—up to a million-fold stronger than previously reported—the research team successfully inhibited the pathological activity of IDPs. This marks a paradigm shift, transforming a perceived boundary in molecular pharmacology into fertile ground for therapeutic innovation.

Central to their investigation is the androgen receptor (AR), a disordered protein whose aberrant activity drives the progression of the majority of prostate cancers. Unlike conventional drugs that target stable receptor domains, the researchers crafted molecules that interact with the receptor’s intrinsically disordered transactivation domain. By effectively “freezing” this mobile region in an inactive conformation, these compounds prevent the AR from activating gene expression programs that fuel cancer proliferation.

This strategy required overcoming formidable scientific challenges. Disordered proteins’ lack of fixed binding sites renders classical rational drug design ineffective. Dr. Marianne D. Sadar, the principal investigator, emphasizes the complexity of this endeavor by likening IDPs to “moving strands of spaghetti” rather than static locks. The team’s extensive expertise, cultivated over decades, laid the groundwork for this success, having previously developed the first compound targeting IDPs in 2008 and progressed others into clinical trials, a world-first milestone.

Through iterative molecular modifications and rigorous biochemical assays, several candidate compounds emerged, demonstrating potent antagonism of the androgen receptor in vitro. Subsequent in vivo assessments in animal models revealed that these novel molecules suppressed prostate tumor growth more effectively than established therapies. This enhanced efficacy was especially notable in models resistant to current treatment options, underscoring the potential to address drug resistance—a major hurdle in oncology.

The implications extend beyond prostate cancer. Intrinsically disordered proteins are integral to numerous signaling pathways implicated in diverse diseases. By establishing a methodological framework to pharmacologically modulate these elusive targets, this discovery could unlock therapeutic avenues across oncology, neurology, cardiology, and immunology. The approach redefines what constitutes a druggable target, expanding the molecular landscape accessible to medicinal chemists.

Dr. Natalie Strynadka, a co-author and professor of biochemistry, highlights the remarkable binding affinity achieved, describing it as a “major achievement” that challenges and expands conventional wisdom in protein-ligand interactions. Complementing this, Dr. Raymond Andersen, a chemistry expert, remarked on the surprising efficacy of these molecules in stabilizing highly dynamic protein regions, achieving functional inhibition where previous drugs faltered.

Looking forward, the research team aims to transition their most promising candidates into clinical evaluation, with the goal of providing prostate cancer patients with treatments that not only improve efficacy but also reduce side effects. Early intervention with these drugs could transform patient outcomes by effectively neutralizing AR-driven oncogenic signals before the emergence of resistance.

Beyond clinical translation, this innovation has profound consequences for the broader drug discovery community. By demonstrating that highly flexible, disordered protein domains can be locked into therapeutic conformations, it challenges the dogma that only well-structured proteins are viable drug targets. This could catalyze a wave of research endeavors focusing on previously neglected protein classes, accelerating the development of drugs for a variety of hitherto refractory conditions.

This research was supported by the U.S. National Institutes of Health (NIH)/National Cancer Institute (NCI) as well as donations from Country Meadows Senior Men’s Golf Charity and the BC Cancer Foundation, underscoring the collaborative nature of cutting-edge biomedical research. The team’s multidisciplinary expertise in biochemistry, molecular biology, and chemistry was crucial for the success of this interdisciplinary project.

In summation, this achievement opens an inspiring new frontier in precision medicine. By drugging the “undruggable,” the researchers have not only forged new weapons against prostate cancer but also illuminated a path forward for numerous other diseases driven by intrinsically disordered proteins. The promise of converting molecular complexity into druggable vulnerability may soon translate into tangible clinical benefits, reshaping therapeutic landscapes across the biomedical field.

Subject of Research: Cells

Article Title: Drugging the intrinsically disordered transactivation domain of androgen receptor

News Publication Date: 27-Apr-2026

Web References:

• Nature Signal Transduction and Targeted Therapy – DOI:10.1038/s41392-026-02642-3

Keywords: Drug discovery, Cancer, Prostate cancer, Proteins, Signal transduction, Protein interactions, Drug resistance, Pharmacology, Molecular biology